Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17710287 | 1.00 | SLC6A4 (0.36) | SLC6A4RIPK1MAOANPC1RAB9A | |
| SCHEMBL28725351 | 1.00 | SLC6A4 (0.36) | SLC6A4RIPK1MAOANPC1RAB9A | |
| SCHEMBL29488706 | 1.00 | SLC6A4 (0.36) | SLC6A4RIPK1MAOANPC1RAB9A | |
| SCHEMBL21570469 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL21570471 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL17710306 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL21570467 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL17710305 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL29488715 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL29488689 | 0.84 | SLC6A4 (0.34) | SLC6A4MAOANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230523-A | Benzimidazole derivatives as modulators of ROR-gamma | 生命医药有限责任公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3939974-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3408268-B1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11001583-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200231597-A1 | BICYLIC COMPOUND ACTING AS AN INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-23 | — | — | US | disclosed |
| US-20200079767-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-03-12 | — | — | US | disclosed |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2019-11-21 | — | — | US | disclosed |
| EP-3408268-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017132432-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-9663515-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001583-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | SLC6A4 4687/4885RIPK1 1464/4885MAOA 4051/4885 |
| US-20190352286-A1 | BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | SLC6A4 4690/4885RIPK1 1682/4885MAOA 4091/4885 |
| US-10829481-B2 | Benzimidazole derivatives as modulators of ROR-gamma | RORB, RORC, RORA | SLC6A4 4744/4885RIPK1 2063/4885MAOA 4102/4885 |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | SLC6A4 4687/4885RIPK1 1464/4885MAOA 4051/4885 |
| US-20200079767-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | SLC6A4 4687/4885RIPK1 1464/4885MAOA 4051/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | SLC6A4 4810/4885RIPK1 1933/4885MAOA 4572/4885 |
| US-20200231597-A1 | BICYLIC COMPOUND ACTING AS AN INHIBITOR | RORC, RORB, RORA | SLC6A4 4497/4885RIPK1 651/4885MAOA 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.